Three patients, each of whom had required intensive open-ended antimicrobial therapy for control of the symptoms of chronic relapsing neurological Lyme disease and relapsing babesiosis, were able to discontinue treatment and remain clinically well for periods of observation of 6–23 months following the completion of a finite course of treatment solely with disulfiram. One patient relapsed at six months and is being re-treated with disulfiram.

https://doctors4covidethics.org/blog/

"

.UK attorney Anna de Buisseret today announced serving Notices of Liability on COVID-19 clinics and individuals administering the experimental biological agent known as the “COVID-19 vaccine” without obtaining fully informed consent, freely given in accordance with the Nuremberg Code and UK and International law.

Results: Thirty-six published papers have used systemic insecticides/endectocides for mosquito control. Most of the studies (56.75%) were done on Anopheles gambiae complex species on doses from 150 μg/kg to 400 μg/kg in several studies. Target hosts for employing systemic insecticides/drugs were animals (44.2%, including rabbit, cattle, pig, and livestock) and humans (32.35%).

Conclusions: Laboratory and field studies have highlighted the potential of endectocides in malaria control. Ivermectin and other endectocides could soon serve as novel malaria transmission control tools by reducing the longevity of Anopheles mosquitoes that feed on treated hosts, potentially decreasing Plasmodium parasite transmission when used as mass drug administration (MDA).

In other words, this means that there is a possibilty ro erradicate Malaria in certain areas by giving Ivermektin to animals and humans, thereby killing the Malaria mosquitos!

This article shows no evidence of asymptomatic spread of Covid 19 among 10 million participants in Wuhan, China.

Magnetic graphene oxide, a compound of magnetic nanoparticles and graphene oxide, possesses distinct physical and chemical characteristics, including nano size, a large specific surface area, paramagnetic and biocompatible properties, making it a promising biomaterial in the field of biomedicine. In particular, its excellent characteristics, including the integration of specific photothermal properties, magnetic thermal properties, paramagnetism, active chemical bonds, hydrophilicity, and low cytotoxicity, have been applied to remarkable bio-applications in bioimaging, biosensors, biochemical extraction and separation, stem cell regulation and the induction of differentiation, targeted drug delivery, and cancer therapy. In this review, we concentrate on the approaches of preparation, fundamental structures, biocompatibility, and the biomedical applications of magnetic graphene oxide composites. 

Abstract Purpose: To develop and disseminate HIT evidence and evidence-based tools to improve healthcare decision making through the use of integrated data and knowledge management. Scope: To create a generalizable system to facilitate detection and clinician reporting of vaccine adverse events, in order to improve the safety of national vaccination programs. Methods: Electronic medical records available from all ambulatory care encounters in a large multi-specialty practice were used. Every patient receiving a vaccine was automatically identified, and for the next 30 days, their health care diagnostic codes, laboratory tests, and medication prescriptions were evaluated for values suggestive of an adverse event. Results: Restructuring at CDC and consequent delays in terms of decision making have made it challenging despite best efforts to move forward with discussions regarding the evaluation of ESP:VAERS performance in a randomized trial and comparison of ESP:VAERS performance to existing VAERS and Vaccine Safety Datalink data. However, Preliminary data were collected and analyzed and this initiative has been presented at a number of national symposia. 

Preliminary data were collected from June 2006 through October 2009 on 715,000 patients, and 1.4 million doses (of 45 different vaccines) were given to 376,452 individuals. Of these doses, 35,570 possible reactions (2.6 percent of vaccinations) were identified. This is an average of 890 possible events, an average of 1.3 events per clinician, per month. These data were presented at the 2009 AMIA conference. In addition, ESP:VAERS investigators participated on a panel to explore the perspective of clinicians, electronic health record (EHR) vendors, the pharmaceutical industry, and the FDA towards systems that use proactive, automated adverse event reporting. Adverse events from drugs and vaccines are common, but underreported. Although 25% of ambulatory patients experience an adverse drug event, less than 0.3% of all adverse drug events and 1-13% of serious events are reported to the Food and Drug Administration (FDA). Likewise, fewer than 1% of vaccine adverse events are reported. Low reporting rates preclude or slow the identification of “problem” drugs and vaccines that endanger public health. New surveillance methods for drug and vaccine adverse effects are needed. Barriers to reporting include a lack of clinician awareness, uncertainty about when and what to report, as well as the burdens of reporting: reporting is not part of clinicians’ usual workflow, takes time, and is duplicative. Proactive, spontaneous, automated adverse event reporting imbedded within EHRs and other information systems has the potential to speed the identification of problems with new drugs and more careful quantification of the risks of older drugs. Unfortunately, there was never an opportunity to perform system performance assessments because the necessary CDC contacts were no longer available and the CDC consultants responsible for receiving data were no longer responsive to our multiple requests to proceed with testing and evaluation.

Evidence of transmission of SARS-CoV-2 from patients who remain asymptomatic (as opposed to pre-symptomatic) is found in a body of numerous meta-analyses. Evidence of asymptomatic transmission has been based on only a handful of instances which themselves are questionable. The existence of transmission of SARS-CoV-2 from asymptomatic individuals has become an accepted truth but the evidence for this phenomenon being anything other than mistaken interpretation of false positive test results is weak. Examination of the underlying data from the most frequently-cited such meta-analyses reveals that the conclusions are based on a surprisingly small number of cases (six in total globally) and, moreover, the possibility that they are all coincidental contacts with false positive results cannot be ruled out. Transmission which is pre-symptomatic is rare and represents a negligible risk to the population. It is questionable therefore whether any of the extensive testing, tracing, isolation and lockdown policies have delivered any worthwhile benefit over and above strategies which seek to advise symptomatic individuals to self-isolate.

EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials

Summary:

6. Regarding "The Vaccines". It has been clearly shown that the Covid 19 vaccines are neither safe, nor effective, with tens of thousands of deaths already officially registered, meaning that the real number probably is 10-100 times higher, as it is a known fact that doctors don´t report most of the side effect and deaths from vaccines, due to time restraints , social pressure and lack of appropriate collection of data from vaccinated individuals, with performed follow up lab tests like D-dimer and lack of structured follow up with health questionnaires at certain time intervals, which is the case in all "normal phase III studies